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Abstract 
Background: cool and dry gas insufflation during laparoscopy induces 
hypothermia and cytokine increase, with significant perioperative morbidity. Few 
studies have suggested that warmed and humidified insufflation leads to an 
improved body core temperature (BCT) maintenance, a reduction of the 
inflammatory response and an improved quality of postoperative course, 
compared with standard insufflation. 
Objective: to assess if warmed and humidified CO2 insufflation with 
HumiGard™ device can achieve significant benefits over standard insufflation in 
terms of risk of hypothermia and cytokine response, in the setting of robot-
assisted radical prostatectomy (RARP). 
Design: prospective, randomized, controlled clinical trial (September, 2015, 
June, 2016). 
Setting: single center study in a tertiary hospital. 
Participants: 64 patients with prostate cancer undergoing RARP were 
randomized, 32 to the treatment group and 32 to the control group. 
Intervention: the treatment group (H+WB) received warmed, humidified CO2 
insufflation with HumiGard™ device, plus hot air warming blanket; the control 
group (WB) received standard CO2 insufflation, plus hot air warming blanket. 
 Main outcomes and measures: BCT, plasma levels of cytokines IL-6 and 
TNF-α, pain scores, and intraoperative parameters. The data were analyzed 
according to the Bayesian paradigm. 
Results: intraoperative BCT increased in both groups during surgery, with a 
statistically significant difference favoring group H+WB, ending at 0.2°C higher 
on average than group WB. The overall BCT increase was 0.088 degree per hour 
in the WB group, with an additional 0.064 degree per hour in the H+WB group. 
No difference across groups, at none of the time points, could be shown as far as 
mean serum cytokine levels was concerned. No statistical differences were noted 
for pain scores and the other intraoperative parameters. 
Conclusions: during RARP, warm and humidified CO2 insufflation with the 
HumiGard™ device was more effective than the standard CO2 insufflation in 
maintaining the patient’s heat homeostasis, even if the difference was minimal. 
No benefit could be shown in terms of cytokine levels and pain scores. 
Trial registration: Clinicaltrials.gov Identifier: NCT02586974 
 
 
 
 
 
 
 
 
  
 
Contents 
1. Effects of warmed, humidified CO2 insufflation on body core temperature and 
cytokine response: head-to-head comparison  versus standard insufflation 
during robot-assisted radical prostatectomy ...................................................... 1 
1.1 Introduction ............................................................................................. 1 
1.1.1 Preliminary data ................................................................................ 2 
1.1.2 Study aims ......................................................................................... 3 
1.2 Methods ................................................................................................... 4 
1.2.1 Study design ...................................................................................... 4 
1.2.2 Study endpoints ................................................................................. 6 
1.2.3 Standardized anesthesia protocol ...................................................... 6 
1.2.4 Standardized surgical protocol .......................................................... 6 
1.2.5 CO2 insufflation device ..................................................................... 9 
1.2.6 Gas conditioning device .................................................................. 10 
1.2.7 Outcome measures .......................................................................... 12 
1.2.8 Statistical analyses .......................................................................... 12 
1.3 Results ................................................................................................... 14 
1.3.1 Body core temperature .................................................................... 15 
1.3.2 Cytokines ........................................................................................ 16 
1.3.3 Postoperative parameters and complications .................................. 17 
1.4 Discussion .............................................................................................. 20 
 1.5 Conclusion ............................................................................................. 24 
2. References ........................................................................................................ 25 
  
 
List of Figures 
 
Figure 1: Benefit of warm and humidified insufflation (F&P H) versus 
humidified (aeroneb) or standard insufflation in terms of prevention of 
hypothermia. ............................................................................................................ 3 
Figure 2: CONSORT flow diagram .................................................................. 5 
Figure 3: steps of RARP.................................................................................... 8 
Figure 4: Airseal System ................................................................................... 9 
Figure 5: Fisher and Paykel (F&P) HumiGard™ Surgical Humidification 
System .................................................................................................................... 11 
Figure 6: profiles for body core temperature .................................................. 15 
Figure 7: profiles for cytokines IL-6 (B) and TNF-alfa (C) ............................ 17 
  
 
List of Tables 
 
Table 1. Baseline patient characteristics and intraoperative data.................... 14 
Table 2. Baseline patient characteristics and intraoperative data.................... 16 
Table 3. Pain scores ......................................................................................... 18 
Table 4. Postoperative recovery parameters and complications ..................... 19 
Table 5. Main studies evaluating warm and/or humidified gas conditioning . 21 
Table 6. Main studies evaluating warm and/or humidified gas conditioning . 22 
 
 
 
  
 
Chapter 1 
Effects of warmed, humidified CO2 
insufflation on body core 
temperature and cytokine 
response: head-to-head comparison  
versus standard insufflation during 
robot-assisted radical 
prostatectomy 
1.1 Introduction 
The most commonly used gas for insufflation during laparoscopic surgery is CO2, 
which is colorless, odorless and non-inflammable. The major advantage of CO2 is 
its rapid dissolution in the event of venous emboli, while hemodynamic and acid-
base changes are usually mild and clinically negligible for most patients. 
Among the possible consequences of cool and dry gas insufflation during 
laparoscopic procedures are hypothermia and cytokine increase, which might 
cause significant perioperative morbidity [1]. More in detail, body core 
temperature (BCT) decrease during laparoscopic surgery has been calculated in 
humans as 0.3°C for every 50 L of cold and dry insufflation gas [2]. The reported 
temperature drop is caused by redistribution of heat and heat loss, both non-
specific (due to anesthesia and environmental patient exposure) and specific (due 
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to peritoneal dry and cool insufflation) [3]. The resulting hypothermia can be 
severe, particularly after prolonged surgery. As for cytokine response, an increase 
of several pro-inflammatory cytokines has been described following the irritating 
effect of peritoneal CO2 insufflation.  
In the last years, various devices providing heating and/or humidification of 
the insufflated gas have been investigated to evaluate the specific heat losses 
resulting from peritoneal insufflation, as well as the inflammatory response. 
Previous studies conducted on animal models and human setting have suggested 
that warmed and humidified insufflation leads to an improved BCT maintenance, 
a reduction in the degree of inflammatory response and an improved quality of 
postoperative course, compared with standard insufflation [3-10]. These findings, 
however, are still not conclusive as they have not been confirmed by adequate 
randomized controlled trials (RCTs). Furthermore, no device providing warming 
and humidification has demonstrated a conclusive advantage over standard cold, 
dry gas in terms of prevention of hypothermia during laparoscopy in the human 
setting [11, 12]. 
 
1.1.1 Preliminary data 
Warm, humidified CO2 should maintain the physiological moist condition of 
the peritoneal cavity, reducing the risk of complications due to cold and dry gas 
insufflation. Nevertheless, according to a recent Cochrane review including 
twenty-two randomized controlled trials, heated and humidified gas insufflation 
would have only minimal benefit on body core temperature, achieving a small 
difference of 0.31°C in comparison to the cold CO2 group, unlikely to be of 
clinical significance. Non statistically significant differences were found in terms 
of postoperative pain, length of hospitalization, or morphine consumption. 
However, the authors stated that the results of this review should be interpreted 
with caution due to the heterogeneity of studies in terms of design, insufflation 
gas temperatures, gas volumes, devices used and location of temperature probes 
[12]. 
The debate about the usefulness of warmed and humidified insufflation has 
continued in the last years, but no definitive conclusions have been drawn. The 
studies conducted up-to-date are quite heterogeneous in surgical indications, type 
of patients enrolled and devices adopted. Furthermore, adequate randomized 
controlled trials evaluating the use of warming and humidification in a prolonged 
laparoscopic surgery are scarce, and often not controlled for the use of an external 
patient warming device such as a warming blanket.  
Recently, an experimental study conducted on pigs has shown that a device 
providing heating and humidification is more effective than humidification alone 
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in preventing heat loss. According to this study, heated and humidified CO2 was 
effective in reducing heat loss for procedures longer than 60 minutes [6, figure 1]. 
Peritoneal irritation due to the cooling and desiccating effect of standard 
insufflations is difficult to assess in terms of cytokine response. Several 
investigators have reported that the serum and peritoneal levels of the pro-
inflammatory cytokines IL6 and TNF-alfa as well as serum levels of cortisol and 
glucose increase after surgery and correlate with the magnitude of surgical stress. 
Indeed, in animal models and clinical settings a trend has been shown toward the 
decreased activation of pro-inflammatory cytokines after laparoscopic procedures 
as compared with open surgery [5]. In this sense, the use of warmed, humidified 
CO2 has been suggested to be associated with a decreased local pro-inflammatory 
cytokine response. Again, however, these findings have not been confirmed; 
according to an experimental study, while preserving body core temperature, 
humidified, warmed CO2 did not affect local or systemic trends of pro-
inflammatory mediators [5]. Available evidence is still inconclusive. 
 
 
Figure 1: Benefit of warm and humidified insufflation (F&P H) versus humidified 
(aeroneb) or standard insufflation in terms of prevention of hypothermia. 
 
1.1.2 Study aims 
Aim of this prospective, randomized study was to assess if warmed and 
humidified CO2 insufflation with HumiGard™ device can achieve significant 
benefits over standard insufflation in terms of risk of hypothermia and cytokine 
response, in the setting of robot-assisted radical prostatectomy (RARP). 
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1.2 Methods 
1.2.1 Study design 
This was a prospective, single-blinded, RCT. All patients undergoing RARP at 
Città della Salute e della Scienza Hospital between September 2015 and June 
2016 were screened for inclusion. Exclusion criteria were as follows: age >80 
years, ASA status >3, allergic status needing corticosteroid premedication, refusal 
to sign the informed consent, cognitive disability, conversion to open surgery. 
Enrolled patients were randomized into two groups, as shown by CONSORT 
Diagram (figure 2): 
- Group H+WB (32 patients) received warmed, humidified CO2 
insufflation with the HumiGard™ device, along with the hot air warming 
blanket routinely used in our institution (forced air warming blanket at 
40°C: Smiths Medical® applied on neck and upper thorax). 
- Group WB (32 patients) received standard CO2 insufflation, along with 
the hot air warming blanket routinely used in our institution (forced air 
warming blanket at 40°C: Smiths Medical® applied on neck and upper 
thorax). 
The study was single-blinded as patients were not told about which system 
was used to maintain BCT homeostasis during surgery. 
The study was granted Institutional Ethics approval in September 2015 
(committee reference number 894/2015). The trial was prospectively registered 
online on ClinicalTrials.gov (NCT02586974, 23/10/2015, principal investigator dr 
Marco Oderda). 
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Figure 2: CONSORT flow diagram 
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1.2.2 Study endpoints 
The primary goal was to evaluate whether the HumiGard™ device is more 
effective than standard CO2 insufflation in maintaining BCT of patients 
undergoing RARP. 
Secondary endpoints were to evaluate if the HumiGard™ device affects the 
response of the pro-inflammatory cytokines IL6 and TNF-α, and if it is beneficial 
in terms of postoperative pain, bowel transit and hospital stay. 
 
1.2.3 Standardized anesthesia protocol 
Premedication was done with midazolam. Induction of anesthesia was performed 
with Sufentanil (0.3γ/kg) and Propofol (2-2.5 mg/kg). Muscle relaxation was 
obtained with a bolus of Rocuronium (0.5-0.6 mg/kg). After tracheal intubation, 
maintenance was performed with Sevoflurane (MAC 0.8-1). Intraoperative 
analgesia was obtained with Sufentanil and deep neuromuscular blockade was 
achieved with Rocuronium infusion. Patients were ventilated with Pressure 
Regulated Volume-Controlled mode (ventilator Flow-i Maquet), with a tidal 
volume of 8 ml/kg and a frequency of 14-16/min. Adjustments of the ventilatory 
setting were made according to the measured peak and plateau pressures, serial 
blood gas analyses, and arterial-to-end-tidal CO2 pressure gradients. At the end of 
surgery, reversal of neuromuscular blockade was obtained with Sugammadex 
according to train-of-four (TOF) values.  
Around one hour before the end of surgery, Paracetamol 1g plus Tramadol 
100mg were administered. Post-operative analgesia was accomplished with 
continuous infusion of Tramadol 300mg/die (4-5 mg/kg/die) by elastomeric pump 
and Paracetamol 1g/8h bolus IV for 48 hours. Rescue therapy consisted of 
Ketorolac 30 mg bolus IV. Postoperative nausea/vomiting was managed with 
Alizapride. Antibiotic and anti-thrombotic prophylaxis were routinely performed. 
All fluids injected were at ambient temperature. 
 
1.2.4 Standardized surgical protocol 
All patients underwent RARP in steep Trendelenburg position, with or without 
pelvic lymph node dissection (PLND) according to the clinical case and the tumor 
risk class. Surgeries were performed by two urologists expert in robotics, with an 
experience of more than 100 RARP.  
Patient preparation: after inducing general anesthesia, the patient is 
placed in modified lithotomic position, with the legs abducted and parallel to the 
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level of the bed. A 20Ch Foley catheter is inserted and the catheter balloon 
inflated with 5 ml. A 30-degree Trendelenburg position is obtained in order to 
displace the small bowel from the pelvic area. Pneumoperitoneum is established 
with an insufflation pressure of 15 mmHg. After trocar placement, insufflation 
pressure is maintained between 10 and 12 mmHg. Six trocars are placed: a 12-mm 
camera port 2 cm above the umbilicus, two 8-mm robotic ports bilaterally at a 
distance of at least 8 cm from the camera port, a third 8-mm robotic port 5 cm 
above the left anterior superior iliac spine. Finally, two 5-mm assistant ports are 
triangulated above the right robotic port. Afterwards, the robot with a 0° lens (4-
arms Da Vinci Si Surgical System, Intuitive Surgical, Inc, Sunnyvale, CA, USA) 
is docked.  
Robotic-assisted radical prostatectomy (RARP): before dropping down 
the bladder, care must be taken to have a free Douglas pouch in order to have a 
proper exposure to the prostate once the Retzius space is developed. We start by 
dividing the two umbilical arteries and the urachus as high as possible, the Retzius 
space is dissected in an avascular plane and the fat covering the prostate removed 
so that we identify the landmarks that help approaching the prostate laterally. 
Endopelvic fascia is incised bilaterally in order to isolate prostatic apex. The 
Santorini plexus is prudentially sutured with a Vycril 0 double stitch. Bladder 
neck is then identified and opened, possibly with a bladder neck-sparing 
approach. Successively, we gain access to the plane of seminal vesicles and vas 
deferens, which are isolated and dissected. Prostato-rectal space is developed until 
the prostatic apex. Postero-lateral dissection of the prostate is performed, 
according to clinical cases, either with an extrafascial, non nerve-sparing approach 
or with a nerve-sparing approach, with neurovascular bundles preservation. The 
apex dissection is completed and the urethra is divided, avoiding an extensive 
dissection from the surrounding muscle fibers. Vesico-urethral anastomosis is 
performed either with a 30-cm 3-0 V-loc, 17mm, ½ c, or with two running sutures 
with 18-cm 3-0 Monocryl, 26mm, ½ c. At the end of surgery, exsufflation of gas 
is performed before removing the trocars. The umbilical incision for the optical 
trocar is slightly enlarged for specimen removal. 
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Figure 3: steps of RARP: 3A. Opening of Douglas pouch. 3B. Section of vas 
deferens. 3C. Exposition of the angle between prostate, neurovascular bundle (NVB) and 
seminal vesicle. 3D. Section of seminal vesicle tip. 3E. Section of bladder neck. 3F. 
Isolation of urethra. 3G. Section of urethra. 3H. Urethro-vesical anastomosis. 
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Pelvic lymph node dissection (PLND): it is performed only when needed, 
according to the tumor risk class. We usually carry out the PLND prior to RARP, 
as we prefer to work in a “cleaner” operative space. We start by incising the 
peritoneum over the perceived area of the external iliac artery, lateral to the 
umbilical artery. The incision is cranially extended following the external and the 
common iliac artery until we reach the ipsilateral ureter. On the left side, we must 
previously free the sigmoid colon to gain access to the iliac vessels and the ureter. 
The lymphatic tissue overlying the external iliac vessels is longitudinally incised, 
and the vessels are skeletonized so that the lymph nodes can be released and 
removed en bloc. The lateral border of our dissection is represented by the genito-
femoral nerve, whereas the distal limit is represented by the Cloquet node. The 
paravesical space lateral to the umbilical artery is opened until the origin of this 
artery from the internal iliac artery. This plane represents the medial border of our 
PLND. The lymphatic tissue is cleared out from the area of the iliac bifurcation 
and around the internal iliac artery. The internal iliac nodes are often coalesced 
with the obturator packet. The obturator nerve is identified distally underneath the 
pubic bone and the Cooper ligament. It is proximally dissected and all the 
lymphatic tissue is removed from the obturator fossa. The specimens are inserted 
in endobags. 
 
1.2.5 CO2 insufflation device  
Airseal System (SurgiQuest, Milford, USA), used in standard modality of 
insufflation at 10-12 mmHg. 
 
 
Figure 4: Airseal System (SurgiQuest, Milford, USA) 
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1.2.6 Gas conditioning device 
Fisher and Paykel (F&P) HumiGard™ Surgical Humidification System, including 
F&P HumiGard™ MR860AEU surgical humidifier, F&P HumiGard™ ST310 
humidified tubing set and 900ST100 Adapter.  
HumiGard™ Surgical Humidification System was given to Città della Salute 
e della Scienza Hospital for free by Fisher and Paykel as a loan in the setting of 
clinical study. The costs of Humigard technology, including the cost of 
purchasing the equipment, tubing kits for each patient and the costs of training 
nurse staff, were estimated at £80.6 per treatment [14]. 
CO2 gas from the insufflator passes through the software-controlled 
humidification chamber, filled with 30 cc of saline water and sitting on a heater 
plate, where it actively picks up heat and humidity. The conditioned CO2 is then 
delivered to the cannula via a heated insufflation tube to maintain the condition of 
the gas. The temperature of the gas is maintained as it travels along a heated tube 
to the laparoscopic port. The humidifier monitors the temperature and flow rate of 
the gas at the chamber outlet with a probe attachment, controlling the amount of 
power delivered to the heater plate to maintain the chamber set point temperature 
[14]. The system aims to condition the gas to physiological conditions: 37°C body 
temperature and 100% relative humidity to prevent evaporation. 
When the gas enters the peritoneal cavity it will equilibrate with the internal 
abdominal conditions: if the gas is delivered at core temperature and saturated, no 
evaporation or condensation will occur. Condensation occurs when the 
temperature of the saturated gas is higher than the abdominal conditions: in this 
case, the gas will cool to the BCT and the capacity of the gas to hold water vapor 
will reduce, and the excess moisture will fall out as condensate. Conversely, if the 
gas is delivered at the same temperature as BCT with a lower relative humidity, it 
will absorb moisture from the patient until gas saturation. If the gas is delivered at 
a temperature cooler than BCT, it will absorb both heat and moisture from the 
patient to reach equilibrium.  
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Figure 5: Fisher and Paykel (F&P) HumiGard™ Surgical Humidification System 
[14] 
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1.2.7 Outcome measures 
The primary outcome (BCT) was measured intraoperatively at 15-min intervals 
using a disposable esophageal probe (Covidien). Plasma levels of cytokines IL-6 
and TNF-α were evaluated with immunoassays (human sIL-6 instant ELISA, 
eBioscence, Vienna, Austria, and Quantikine® ELISA Human TNF-α, R&D 
Sistems, Minneapolis, MN, USA) just before induction of anesthesia, after 2 
hours of pneumoperitoneum, 2 hours from exsufflation, and 24 hours after 
surgery.   
Pain score was assessed through the 10 points Numeric Pain Rating Scale 
(NRS) at patient awakening, then every 30 minutes in the recovery room, until 
discharge to the ward. Successively, it was measured at 12, 24 and 48 hours, 
including the NRS values 1) at rest, 2) during coughing and 3) on walking where 
appropriate. Shoulder pain was also evaluated.  
Intraoperative data included total operative time, from induction of anesthesia 
till awakening; duration of CO2 insufflation; total volume of CO2 insufflated; 
total volume of fluids infused; blood losses; shivering; Aldrete score. 
Postoperative data included length of hospital stay; time to recovery of gas transit; 
time to liquid diet; time to solid diet; patient satisfaction at the time of discharge 
home. 
All intra- and early postoperative complications were recorded according to 
modified Clavien-Dindo classification [15]. 
 
1.2.8 Statistical analyses 
The data were analyzed according to the Bayesian paradigm. The variances were 
given Gamma priors. Continuous variables (and notably BCT) were analyzed with 
mixed effects models with fixed time and group effects with an interaction term, 
and a random subject effect to take account of the repeated structure of the data. 
This random effect was modeled with a Gaussian hyperprior. For the secondary 
outcomes, continuous variables were analyzed with mean comparison  models 
with Gaussian priors (N (,)) and counts data were analyzed with Poisson 
regression models (Gamma priors). For the continuous variables, a lowly-
informative prior was specified for each specific variable, with a variance such 
that the range of data were within relevant clinical values. Group comparisons on 
categorical data were done based on Beta distributions. Results from previous 
series or publications available were used to provide informative priors. In the 
absence of prior information for estimation of a proportion, a non-informative 
(Be(1;1)) prior and minimally-informative (such as Be(2;2) or Be(2;3) etc) priors 
were used in a sensitivity analysis. The effect size was estimated through absolute 
risk difference with the probability that the absolute risk difference is larger than 0 
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(i.e. in favor of the H+WB group) According to the Bayesian concepts, both an 
effect probability near 1 or near 0 indicates a worthwhile effect. We remind that 
Bayesian analysis does not use the (classical a.k.a. frequentist) p-value and that 
the probability of a worthwhile effect must not be confused with a p-value.  
All computations were done with R, WinBUGS and JAGS statistical software 
in their most up-to-date version at the time the analysis are run with all the 
required packages [16, 17].   
Sample size calculation: the sample size was computed with the Average 
Length Criterion method [18]. The sample size was 30 subjects in each group for 
a total of 60 subjects. Two subjects were added in each group to take account of 
potential loss to follow-up, patient withdrawal and missing data. The sample size 
was computed for an expected proportion of subjects with a BCT larger than 36° 
at the end of surgery. This sample size was obtained with the following 
parameters: an expected average length (EAL) of the posterior credible interval 
for the difference between the two proportions of 0.35 (i.e. 35%), a credibility 
level of 0.95, and the following lowly-informative prior: Beta(5;5) in the H + WB 
group and Be(1;9) in the WB alone group. It must be noticed that the sample size 
was the same for an EAL of 0.40 with non-informative prior Be(1;1) in each 
group. More precisely, the computed sample size was 29 per group in each case, 
rounded upward to 30 per group. Finally, and only for illustrative purpose, a 
frequentist estimation according to Casagrande & Pikes, with a type I error rate of 
5%, a type II error rate of 10% in an equitail test required 31 subjects per group to 
show a difference between 50 and 10%. 
Randomization: the randomization list was obtained with a computer 
random numbers generator, with blocks of 4 patients each. 
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1.3 Results 
Groups were well matched at baseline, with no significant differences in age, 
BMI, ASA, comorbidities, or PLND performed. Baseline patient characteristics 
and intraoperative data are shown in table 1. No statistical differences were found 
between the two groups in terms of operative time, insufflation time, fluid 
infusion or blood losses. An increased CO2 volume infused was seen in group 
H+WB, as a consequence of longer operative and insufflation time in comparison 
with group WB. 
 
Table 1. Baseline patient characteristics and intraoperative data 
BASELINE CHARACTERISTICS 
 Group H+WB (n=32) Group WB (n=32) Pr(H+WB > WB) 
Age, mean (SD) 66.4 (7.0) 64.4 (9.0) 0.837 
Age, median (range) 68 (53-78) 65.5 (40-81) 
BMI, mean in kg/m
2
 (SD) 26.0 (2.0) 26.4 (3.3) 0.632 
ASA score 
- I 
- II 
- III 
 
2 (6.2%) 
27 (84.3%) 
3 (9.3%) 
 
1 (3.1%) 
23 (71.8%) 
8 (25%) 
0.945
1
 
Comorbidities 
- Hypertension 
- Diabetes Mellitus 
- Glaucoma 
- OSAS 
- Cardiopathy 
- Obesity 
 
15 (46.8%) 
0 (0%) 
3 (9.3%) 
3 (9.3%) 
1 (3.1%) 
1 () 
 
20 (62.5%) 
2 (6.2%) 
1 (3.1%) 
3 (9.3%) 
4 (12.5%) 
5 (%) 
 
0.107 
0.119 
0.821 
0.503 
0.100 
0.196 
PLND 
- Yes 
- No 
 
10 (31.2%) 
22 (68.7%) 
 
11 (34.3%) 
21 (65.6%) 
0.397 
INTRAOPERATIVE DATA 
 Group H+WB (n=32) Group WB (n=32) P
1
 
Operative time, min, mean (SD) 
- Total operative time 
- Insufflation time 
 
350.9 (55.9) 
275.0 (48.3) 
 
333.1 (46.7) 
257.4 (56.0) 
 
0.908 
0.931 
Total CO2 volume used, L, mean (SD) 635.5 (316.1) 522.0 (158.1) 0.962 
Total fluid infusions, L, mean (SD) 2460.9 (553.7) 2429.0 (614.4) 0.581 
Blood loss, cc, mean (SD) 224.4 (162.7) 214.5 (177.6) 0.588 
1
 probability that the frequency of ASA score less than 3 is larger in the H+WB group. 
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1.3.1 Body core temperature 
The intraoperative BCT increased in both groups during surgery, with a 
statistically significant difference favoring group H+WB, ending at 0.2°C higher 
on average than group WB (figure 2A). The overall BCT increase was 0.088 
degree per hour in the WB group, with an additional 0.064 degree per hour in the 
H+WB group (table 2, Probability of a positive interaction >0.997).  
 
 
Figure 6: profiles for body core temperature 
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1.3.2 Cytokines 
As for cytokines, there were no significant differences in the mean serum cytokine 
concentrations between groups at different time-points (table 2). In both groups, 
IL-6 increased after 2 hours of insufflation, reaching a peak two hours after 
exsufflation (figure 2B). No statistically significant differences were seen 
between groups for TNF-α, with no interaction although a quadratic effect is seen 
(decrease an increase of TNF-α in the WB group, Pr(effect) = 0.973) (figure 2C). 
 
Table 2. Baseline patient characteristics and intraoperative data 
BODY CORE TEMPERATURE 
 Group H+WB (n=32) Group WB (n=32) Pr(H+WB>WB)* 
BCT, °C, mean 
- Start of surgery 
- After 1h 
- After 2h 
- After 3h 
- After 4h 
- End of surgery 
 
35.73 
35.78 
35.96 
36.11 
36.34 
36.26 
 
35.70 
35.77 
35.90 
36.02 
36.07 
36.06 
0.997 
SERUM IL-6 
 Group H+WB (n=32) Group WB (n=32) Pr(H+WB>WB)* 
Serum IL-6, pg/ml, mean 
- Start of surgery 
- After 2h of pneumoperitoneum 
- 2h from exsufflation 
- 24h after surgery 
 
2.13 
4.61 
29.13 
27.01 
 
2.20 
4.16 
25.91 
23.67 
0.666 
SERUM TNF-α 
 Group H+WB (n=32) Group WB (n=32) Pr(H+WB>WB)* 
Serum TNF-α, pg/ml, mean 
- Start of surgery 
- After 2h of pneumoperitoneum 
- 2h from exsufflation 
- 24h after surgery 
 
5.74 
5.69 
5.44 
6.11 
 
6.29 
5.20 
4.90 
7.24 
0.112 
* Test for the time group interaction 
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Figure 7: profiles for cytokines IL-6 (B) and TNF-alfa (C) 
 
1.3.3 Postoperative parameters and complications 
Concerning postoperative parameters, no statistical differences were seen in terms 
of shivering and Aldrete score at awakening, post-operative pain or shoulder pain 
(table 3). No statistical differences were seen in terms of rescue therapy 
administered in the recovery room. The same goes for length of hospital stay, time 
to recovery of gas transit, time to liquid and solid diet. Patient satisfaction was 
equally high in both groups.  
Complications were experienced by four patients, and none was related to 
HumiGard™ (table 4). 
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Table 3. Pain scores 
Shivering and Aldrete score at awakening 
 Group H+WB 
(n=32) 
Group WB 
(n=32) 
Pr(H+WB>WB) 
Shivering 
Aldrete score 
6 (18.7%) 
9.3 (1.4) 
2 (6.2%) 
9.4 (1.5) 
0.925 
0.931 
PAIN at rest by Numeric Rating Scale 
 Group H+WB 
(n=32) 
Group WB 
(n=32) 
Pr(H+WB>WB)* 
NRS, pain at rest, mean (SD) 
- Patient awakening 
- At 12h 
- At 24h 
- At 48h 
 
2.5 (2.6) 
1.6 (1.8) 
1.3 (1.5) 
0.6 (1.1) 
 
2.3 (2.8) 
1.9 (2.2) 
1.8 (2.1) 
1.1 (1.9) 
 
0.160 
PAIN on coughing 
 Group H+WB 
(n=32) 
Group WB 
(n=32) 
Pr(H+WB>WB)* 
NRS, pain on coughing, 
mean (SD) 
- At 12h 
- At 24h 
- At 48h 
 
2.4 (2.1) 
3.0 (2.1) 
1.6 (1.7) 
 
2.6 (2.4) 
3.4 (2.4) 
2.4 (2.5) 
 
0.205 
PAIN on walking 
 Group H+WB 
(n=32) 
Group WB 
(n=32) 
Pr(H+WB>WB)* 
NRS, pain on walking, mean 
(SD) 
- At 24h 
- At 48h 
 
2.0 (1.9) 
1.2 (1.5) 
 
1.9 (1.8) 
1.2 (1.7) 
 
0.582 
SHOULDER PAIN 
 Group H+WB 
(n=32) 
Group WB 
(n=32) 
Pr(H+WB>WB)* 
NRS, shoulder pain, mean 
(SD) 
- At 12hi 
- At 24h 
- At 48h 
 
0.5 (1.4) 
0.3 (1.5) 
0.4 (1.1) 
 
1.1 (2.1) 
0.8 (1.7) 
0.7 (1.8) 
 
0.687 
* Test for the time group interaction 
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Table 4. Postoperative recovery parameters and complications 
Postoperative recovery parameters 
 Group 
H+WB 
(n=32) 
Group WB 
(n=32) 
Pr(H+WB>WB) 
Length of hospital stay, days, mean (SD) 
- To discharge criteria met 
- To actual discharge 
 
3.3 (1.3) 
3.5 (1.3) 
 
3.2 (1.4) 
3.5 (1.7) 
 
0.549 
0.529 
 Length of hospital stay, days, median 
(range) 
- To discharge criteria met 
- To actual discharge 
 
3 (2-7) 
3 (2-8) 
 
3 (2-9) 
3 (2-11) 
Time to recovery of gas transit, days, mean 
(SD) 
1.7 (0.9) 1.8 (0.5) 0.343 
Time to recovery of gas transit, days, 
median (range) 
2 (1-5) 2 (1-3) 
Time to liquid diet, days, mean (SD) 1.0 (0.2) 1 (0) 0.550 
Time to liquid diet, days, median (range) 1 (1-2) 1 (1-1) 
Time to solid diet, days, mean (SD) 2.4 (0.7) 2.5 (1.0) 0.358 
Time to solid diet, days, median (range) 2 (2-5) 2 (1-6) 
Patient satisfaction 
- Satisfied 
- Moderately satisfied 
- Not satisfied 
 
22 
9 
1 
 
25 
4 
2 
0.145 * 
Complications 
 Group H+WB 
(n=32) 
Group WB 
(n=32) 
Pr(H+WB>WB) 
Patients with complications, N (%) 3 (9.3%) 1 (3.1%) 0.823 
Clavien grade of complications, N 
(%) 
- I 
 
- II 
- III 
 
 
 
 
- IV 
 
N= 1. 
Postoperative urine 
leakage 
N= 0. 
N= 2. 
Intraoperative 
small bowel 
perforation (n=1),  
intraoperative 
haemorrage (n=1). 
N= 0. 
 
N= 0. 
 
N= 0. 
N= 1. 
Intraoperative 
ureteral injury 
 
 
N= 0. 
 
* Test for satisfied versus moderately or not satisfied 
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1.4 Discussion 
The key to comprehend the possible adverse effects of CO2 insufflation resides in 
the properties of this gas, which is easily absorbed, causing hypercarbia and 
respiratory acidosis. Furthermore, it is relatively cold and dry compared with the 
natural environment of the peritoneal cavity (36°C, virtually 100% relative 
humidity) [19]. Dry and cold CO2 is a mild irritant to the peritoneum, causing 
adverse structural alterations to the mesothelial lining, local pH imbalances and 
changes in the macrophage responsiveness, as shown by histological studies [21]. 
These alterations could be responsible for a conscious sensation of pain which has 
been described in patients undergoing awake laparoscopy [22].  
More importantly, dry and cool CO2 insufflation has been linked to a 
peritoneal hypothermia and a drop in BCT, as a result of evaporative heat loss 
from intra-abdominal tissue [23]. Hypothermia can be very dangerous for the 
patient, causing myocardial ischemia, cardiac arrhythmias, generalized 
immunosuppression, disrupted coagulation and increased risk of surgical site 
infections [24]. Thus, the prevention of perioperative hypothermia is essential 
during laparoscopic surgeries and usually involves the use of a forced warm air 
blanket around the patient. This device, however, is often not enough to contrast 
the cooling effect of CO2, considering that the abdomen must remain uncovered 
during abdominopelvic procedures such as RARP. The use of warm and 
humidified CO2 has been proposed to maintain the physiological moist condition 
of the peritoneal cavity and reduce the risk of such complications [25]. Several 
devices providing heating and humidification have been tested in the animal 
setting, showing promising results in terms of heat loss prevention; recently, an 
experimental study conducted on pigs has shown that heated and humidified CO2 
was more effective than humidification alone in preventing heat loss, particularly 
for procedures longer than 60 minutes [6].  
Nevertheless, studies conducted in the human setting have not shown the 
same results. According to a Cochrane review updated in 2016 which included 
twenty-two RCTs, heated and humidified gas insufflation would have only 
minimal benefit on BCT, achieving only a small difference of 0.31°C in 
comparison with standard, cool CO2 insufflation, unlikely to be of clinical 
significance. The authors of this review concluded that while heated, humidified 
gas leads to mildly smaller decreases in core body temperatures, clinically this 
does not account for improved patient outcomes. Therefore, to date no clear 
evidence supports the use of heated gas insufflation in laparoscopic abdominal 
surgery [12]. The debate has continued in the last years, but no definitive 
conclusions have been drawn. The studies conducted up-to-date are quite 
heterogeneous in surgical indications, type of patients enrolled and devices 
adopted. Furthermore, adequate RCTs evaluating the use of warming and 
humidification in a prolonged laparoscopic surgery are scarce, and often not 
controlled for the use of an external patient warming device such as WB.  
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Our study is the first adequately designed to evaluate the usefulness of  warm 
and humidified CO2 for the endpoints considered. Sample size was accurately 
calculated to detect an improvement of 35% in BCT, which could reflect a 
clinically significant benefit given preliminary data obtained during experiments 
with minipigs. We chose HumiGard™ following the promising findings of Noll et 
al, who discovered in an animal setting an advantage of this device in preventing 
heat loss for laparoscopic procedures longer than 60 minutes [6]. In the human 
setting, only a few RCTs [8, 9, 26] have investigated the usefulness of 
HumiGard™, and none has shown significant benefits except for a reduction of 
postoperative pain [26], as shown by Table 5 and 6.  
 
Table 5A. Main studies evaluating warm and/or humidified gas conditioning 
Author, year Setting N Gas 
conditioning 
 
Device 
HUMAN SETTING 
Oderda, 2017 
[current study] 
Human, RCT, 
RARP 
32 (Humigard 
+ WB) 
 
32 (WB) 
Heating and 
humidification 
Humigard 
Koninckx, 2013 
[26] 
 
Human, RCT, 
laparoscopic deep 
endometriosis 
excision 
25 (Humigard) 
 
18 (controls) 
Humidification 
only 
Humigard 
modified 
Tzu-Chieh, 2013 
[9] 
Human (children), 
RCT, laparoscopic 
appendicectomy 
97 (Humigard) 
 
98 (controls) 
Heating and 
humidification 
Humigard 
Sammour, 2010 
[8] 
Human, RCT, 
laparoscopic colonic 
surgery 
41 (Humigard) 
 
41 (controls) 
Heating and 
humidification 
Humigard 
Benavides, 2009 
[30] 
Human, RCT, 
laparoscopic gastric 
banding 
40 (Stryker) 
38 (Insuflow) 
 
35 (controls) 
Heating only 
Heating and 
humidification 
Stryker 
Insuflow 
Davis, 2006 [4] Human, RCT, 
laparoscopic gastric 
bypass 
11 (Stryker) 
11 (Insuflow 
modified) 
11 (Insuflow) 
 
11 (controls) 
Heating only 
Humidification 
only 
Heating and 
humidification 
Stryker 
Insuflow 
modified 
Insuflow 
Farley, 2004 
[29] 
Human, RCT, 
laparoscopic 
cholecystectomy 
52 (Insuflow) 
 
49 (controls) 
Heating and 
humidification 
 
Insuflow 
Nguyen, 2002 
[23] 
Human, RCT, 
Nissen 
fundoplication 
10 (Insuflow) 
 
10 (controls) 
Heating and 
humidification 
 
Insuflow 
Mouton, 1998 
[28] 
Human, RCT, 
laparoscopic 
10 (modified 
insufflator) 
Heating and 
humidification 
Modified 
LINS-1000 
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cholecystectomy  
10 (controls) 
 insufflator 
Ott, 1998 [7] Human, laparoscopic 
surgery 
36 (Insuflow) 
 
36 (controls) 
Heating and 
humidification 
Insuflow 
ANIMAL SETTING 
Noll, 2012 [6] Pigs 16 (each pig 
acting as it 
own control) 
Heating and 
humidification 
Humidification 
only 
Humigard 
 
Aeroneb 
Schlotterbeck, 
2011 [10] 
Pigs 4 (each pig 
acting as it 
own control) 
Heating and 
humidification 
Humidification 
only 
HME-Booster 
Aeroneb 
Schlotterbeck, 
2008 [3] 
Pigs 4 (each pig 
acting as it 
own control) 
Heating and 
humidification 
Humidification 
only 
Pall system 
 
Aeroneb 
Margulis, 2005 
[5] 
Pigs, laparoscopic 
nephrectomy 
5 (Insuflow) 
5 (anti-
inflammatory) 
5 (controls) 
Heating and 
humidification 
Insuflow 
 
Table 6. Main studies evaluating warm and/or humidified gas conditioning 
Author, year Outcomes of gas conditioning 
Temperature Cytokines Pain or other 
HUMAN SETTING 
Oderda, 2016 
[current study] 
Significant difference 
favoring heated and 
warmed insufflation 
No statistical differences in 
mean serum levels of IL-6 
and TNF-α 
No statistical differences in 
pain scores 
Koninckx, 2013 
[26] 
 
Not investigated Not investigated Less postoperative pain and 
reduction of adhesions 
Tzu-Chieh, 2013 
[9] 
Not investigated Not investigated No significant differences in 
pain (VAS score) or opiate 
consumption 
Sammour, 2010 
[8] 
No significant 
differences in BCT 
No differences in cytokine 
concentrations (IL-6, IL-1, 
TNF-α, IL-8, IL-10) 
No significant differences in 
MEDD usage, or any recovery 
parameters 
Benavides, 2009 
[30] 
Not investigated Not investigated Warm and humidified gas 
reduces shoulder pain, 
shortens length of stay and 
decreases pain meds 
requirements 
Davis, 2006 [4] No significant 
differences in BCT 
Not investigated No significant differences in 
pain scores or length of 
hospital stay 
Farley, 2004 [29] Significantly less 
intraoperative 
Not investigated Significantly less 
postoperative abdominal pain 
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hypothermia 
Nguyen, 2002 
[23] 
No significant 
differences in BCT 
Not investigated No significant differences in 
pain (VAS score) or opiate 
consumption 
Mouton, 1998 
[28] 
No significant 
differences in BCT 
Not investigated Significantly less 
postoperative pain (VAS 
score) 
Ott, 1998 [7] Less intraoperative 
hypothermia 
Not investigated Reduced length of stay and 
postoperative pain. 
ANIMAL SETTING 
Noll, 2012 [6] Less heat loss for 
procedures longer than 
60 minutes; more 
effective than 
humidification only  
Not investigated Not investigated 
Schlotterbeck, 
2011 [10] 
Less temperature 
decrease as compared to 
standard insufflation 
after 160 minutes; equal 
efficacy as compared to 
humidification only  
Not investigated Not investigated 
Schlotterbeck, 
2008 [3] 
Less temperature 
decrease as compared to 
standard insufflation 
after 160 minutes; equal 
efficacy as compared to 
humidification only 
Not investigated Not investigated 
Margulis, 2005 
[5] 
Higher intraoperative 
and postoperative BCT 
than controls. 
No differences in peritoneal 
or systemic cytokine levels 
(IL-6, IL-1, TNF-α) 
Not investigated 
 
Our RCT showed a statistically significant difference of BCT in favor of 
heated, humidified CO2. However, this advantage became visible only after a 
certain amount of time, and the difference of 0.2°C on average was minimal from 
a clinical point of view: in fact, it did not affect the patient outcomes, in terms of  
cytokine levels, pain scores or other intraoperative parameters. On the other hand, 
this finding can be seen as promising, especially if we consider that our 
HumiGard™ device warmed the CO2 only up to 36°C, and not 37°C as expected. 
As for cytokine response, several investigators have reported that serum 
and peritoneal levels of pro-inflammatory cytokines IL6 and TNF-alfa, as well as 
cortisol and glucose, increase after surgery, as a consequence of surgical stress 
[5]. In laparoscopy, this increase is also linked to the peritoneal irritation due to 
the cooling and desiccating effect of CO2, and could be reduced by the use of 
warmed, humidified CO2 [27]. Only a couple of studies have evaluated this 
aspect: in the animal settings, Margulis et al were not able to find any differences 
in peritoneal or systemic cytokine levels during laparoscopic nephrectomies 
performed with heated and humidified CO2 obtained with Insuflow™ versus 
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standard insufflation [5]. Sammour et al reached the same conclusions on human 
patients undergoing laparoscopic colonic surgery, using the HumiGard™ device 
versus standard insufflations. In our study, we were not able to find significant 
differences in IL-6 and TNF-α concentrations, at different time-points throughout 
the surgery.  
Concerning postoperative parameters, we did not find any significant 
differences in terms of postoperative pain, shoulder pain, nor shivering and 
Aldrete score at awakening. We acknowledge that postoperative pain after RARP 
is usually mild and easily controlled by conventional drugs, so we did not expect 
huge differences in this field. No differences were seen in terms of recovery 
parameters such as length of hospital stay, time to recovery of gas transit or diet, 
and patient satisfaction. A few studies have suggested an improvement in 
postoperative pain, shoulder pain, or pain meds consumption [7, 26, 28-30], but 
others have not confirmed these results [4, 8, 9, 23] (Table 5 and 6).  
Analyzing the results of our RCT, we acknowledge that the benefit of 
HumiGard™ was clinically small. Interestingly, our RCT showed a progressive 
increase of intraoperative BCT during surgery, pointing out that patients 
undergoing RARP have an increased risk of hypothermia at the beginning of the 
procedure. This may be due to the initial steps of robotic surgeries, including the 
docking of the robot, which limit the possibilities of covering the patient with 
standard warming blankets. In this light, conditioning of the insufflation CO2 with 
devices such as Humigard™, used as part of a multimodal heat loss prevention 
strategy, could represent a useful aid to limit the risks of hypothermia. In clinical 
practice, the use of this device has been estimated to be cost-effective if compared 
to standard care, considering also the limited cost of the system [13, 31]. 
Limitations of study were the low baseline BCT of our patients and the 
fact that our HumiGard™ device never reached 37°. Amongst its strengths we 
acknowledge its design as RCT and the diversity of endpoints considered.  
 
1.5 Conclusion 
During RARP, warm and humidified CO2 insufflation with the HumiGard™ 
device was more effective than the standard CO2 insufflation in maintaining the 
patient’s heat homeostasis, even if the difference was minimal and did not alter 
the patient outcomes. Gas conditioning with HumiGard™ did not affect plasma 
levels of pro-inflammatory cytokines IL-6 and TNF-α. No differences were seen 
for postoperative pain and other recovery parameters. 
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